Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vacuolar H<sup>+</sup>-ATPase Preserves Cardiolipin Homeostasis Through the Lysosomal-Mitochondrial Axis to Restrain Cardiac Aging.

Circulation·2026
Same author

Study design and rationale of the Visualizing Subclinical Myocardial Changes with Shear Wave Elastography in Dilated Cardiomyopathy (VISUALIZE-DCM) trial.

European heart journal. Imaging methods and practice·2026
Same author

Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.

European journal of heart failure·2026
Same author

The dual face of lamin A/C cardiomyopathy: risk prediction of heart failure and arrhythmias.

European heart journal·2026
Same author

Insights Into the Natural History of Recurrent Myocarditis, A Multicenter International Study (Re-Myo Study).

Journal of the American Heart Association·2026
Same author

Evaluation and management of recent onset cardiomyopathy in the current era of heart failure therapeutics: a clinical consensus statement of the Heart Failure Association of the ESC.

ESC heart failure·2026
Same journal

Metabolomic and Proteomic Signatures of Cardiorespiratory Fitness for Predicting All-Cause Mortality and Non-Communicable Disease Risk: A Prospective Study in the UK Biobank.

Circulation. Genomic and precision medicine·2026
Same journal

Unlocking the Regulatory Genome: Interpreting the Clinical Impact of Noncoding Variants in Genetic Cardiomyopathies.

Circulation. Genomic and precision medicine·2026
Same journal

Evaluation of the Diagnostic Yield of Exome-Based Panels for Congenital Heart Defects in Different Clinical Settings.

Circulation. Genomic and precision medicine·2026
Same journal

Influence of Genotype on Cardiac Phenotype in Pediatric Hypertrophic Cardiomyopathy.

Circulation. Genomic and precision medicine·2026
Same journal

Cardiomyopathy-Associated Mutations in a Hotspot Region at the C-Terminal Part of Desmin Coil-2 Domain Impair the Intermediate Filament Assembly.

Circulation. Genomic and precision medicine·2026
Same journal

Functional and Molecular Characterization of Novel <i>GDF2 (BMP9</i>) and <i>BMP10</i> Variants From the French PAH and HHT Cohorts.

Circulation. Genomic and precision medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

Metabolic Task Analysis Reveals Distinct Metabotypes in End-Stage Dilated Cardiomyopathy.

Bastien S C Nihant1, Job A J Verdonschot1, Sonia Bălan2

  • 1Cardiovascular Research Institute Maastricht (CARIM), The Netherlands (B.S.C.N., J.A.J.V., J.J.F.P.L., M.N., S.H.).

Circulation. Genomic and Precision Medicine
|July 3, 2026
PubMed
Summary
This summary is machine-generated.

Researchers identified two distinct metabolic subtypes (metabotypes) in dilated cardiomyopathy (DCM) patients using a systems biology approach. This finding advances precision medicine by revealing metabolic heterogeneity in DCM, potentially guiding tailored treatments.

Keywords:
amino acidscalciumhumansinflammationpatient acuity

More Related Videos

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

Related Experiment Videos

Last Updated: Jul 4, 2026

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

Area of Science:

  • Cardiovascular Biology
  • Systems Biology
  • Metabolomics

Background:

  • Dilated cardiomyopathy (DCM) involves cardiac metabolic shifts that vary significantly among patients due to diverse causes.
  • Identifying distinct metabolic subtypes (metabotypes) in DCM is crucial for developing personalized treatment strategies.
  • A practical method to identify DCM metabotypes is needed for advancing precision medicine.

Purpose of the Study:

  • To develop and apply a systems biology approach for uncovering metabolic subtypes (metabotypes) in dilated cardiomyopathy (DCM) patients using transcriptomic data.
  • To investigate the metabolic heterogeneity within end-stage DCM and its relationship with disease etiology and immune responses.

Main Methods:

  • Utilized in silico metabolic modeling optimized for cardiac research to predict metabolic function from enzyme expression.
  • Employed hierarchical clustering on transcriptomic data from end-stage DCM patients and nonfailing controls.
  • Analyzed transcriptome-wide data to identify immune-related differences between identified metabotypes.

Main Results:

  • Identified two distinct metabotypes in end-stage DCM patients characterized by unique alterations in calcium handling, amino acid oxidation, and the pentose phosphate pathway.
  • One DCM metabotype exhibited greater metabolic divergence from controls, suggesting a more significant metabolic contribution to its etiology despite similar disease severity.
  • Transcriptome-wide analysis revealed distinct immune-related profiles between metabotypes, indicating an interplay between inflammation, immunity, and metabolism.

Conclusions:

  • The study confirms the presence of distinct metabotypes in end-stage DCM, highlighting the disease's metabolic heterogeneity.
  • The systems biology approach provides novel insights into DCM progression and etiology, paving the way for targeted therapies.
  • Understanding these metabotypes is essential for advancing precision medicine in DCM.